109 related articles for article (PubMed ID: 2921099)
1. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
Saudek F; Morávek J; Modr Z
Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
[TBL] [Abstract][Full Text] [Related]
2. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
Sheng QS; Lang R; He Q; Yang YJ; Zhao DF; Chen DZ
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):46-9. PubMed ID: 19208514
[TBL] [Abstract][Full Text] [Related]
3. Normal metabolism of morphine in cirrhosis.
Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
[TBL] [Abstract][Full Text] [Related]
4. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure].
Belaieff J; Cochet B; Allaz AF; Rudhardt M; Balant L; Fabre J
Schweiz Med Wochenschr; 1981 Apr; 111(14):502-8. PubMed ID: 6453423
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi K
Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
[TBL] [Abstract][Full Text] [Related]
7. Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis.
Hu OY; Tang HS; Chang CL
J Clin Pharmacol; 1995 Mar; 35(3):250-8. PubMed ID: 7608313
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cefoperazone in healthy volunteers.
Saudek F; Morávek J; Modr Z
Czech Med; 1986; 9(3):162-5. PubMed ID: 3095076
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
[TBL] [Abstract][Full Text] [Related]
10. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
[TBL] [Abstract][Full Text] [Related]
11. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
Birnie GG; Fitzsimons CP; Czarnecki D; Cooke A; Scobie G; Brodie MJ
Hepatogastroenterology; 1985 Aug; 32(4):163-7. PubMed ID: 2865199
[TBL] [Abstract][Full Text] [Related]
12. Temazepam clearance unaltered in cirrhosis.
Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
[TBL] [Abstract][Full Text] [Related]
13. Effect of triglycyl-lysin-vasopressin on quantitative liver function tests in patients with cirrhosis.
Merkel C; Bianco S; Bolognesi M; Caregaro L; Amodio P; Sacerdoti D; Gatta A
Am J Gastroenterol; 1992 Nov; 87(11):1580-6. PubMed ID: 1442677
[TBL] [Abstract][Full Text] [Related]
14. [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].
Bolognesi M; Merkel C; Angeli P; Caregaro L; Gatta A
Minerva Med; 1988 Dec; 79(12):1035-41. PubMed ID: 3211355
[TBL] [Abstract][Full Text] [Related]
15. Changes in metildigoxin pharmacokinetics in cirrhosis of the liver: a comparison with beta-acetyldigoxin.
Rameis H; Woodcock B; Bonelli J; Waginger H
Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):145-51. PubMed ID: 6715083
[TBL] [Abstract][Full Text] [Related]
16. Ranitidine disposition in severe hepatic cirrhosis.
Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic study of a cephalosporin: cefoperazone in patients with a Kehr drain].
Farquet C; Marti MC; Balant L; Cochet B; Rudhardt M; Fabre J; Rohner A
Schweiz Med Wochenschr; 1982 Jan; 112(4):123-9. PubMed ID: 6461067
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of iloprost in patients with hepatic dysfunction.
Hildebrand M; Krause W; Angeli P; Koziol T; Gatta A; Merkel C; Bolognesi M
Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):430-4. PubMed ID: 1701761
[TBL] [Abstract][Full Text] [Related]
19. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cimetidine in patients with liver disease.
González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
